BioCentury
ARTICLE | Emerging Company Profile

Hangzhou Highlightll: Twice the target, hold the tox

TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases

July 3, 2021 2:04 AM UTC

Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer ...



Access this Article